


The Fund aims to achieve long term capital growth primarily through investment in a focussed portfolio of equities issued by companies established in any country and in derivatives, the underlying assets of which are equities issued by companies established in any country.
| Name | % Net Assets |
|---|---|
| Altria Group Inc. | 2.3% |
| Sanofi-Synthelabo | 2.2% |
| British American Tobacco | 2.1% |
| Anheuser-Busch Inbev | 2.1% |
| CBS Corp | 2.0% |
| Amerisourcebergen Corp. | 2.0% |
| Telstra Corp. Ltd. | 2.0% |
| Unitedhealth Group Inc. | 2.0% |
| Novartis | 2.0% |
| Oracle Corp. | 2.0% |
| Key | % Net Assets |
|---|---|
| 2.3% | |
| 2.2% | |
| 2.1% | |
| 2.1% | |
| 91.3% |
| Date | 07-Oct-2022 |
|---|---|
| NAV | $2.17 |
| Currency | USD |
| Change | $0.01 |
| % | 0.44% |
| YTD change | $2.17 |
| YTD % | n/a |
| Fund Inception | 24/02/1998 |
|---|---|
| Fund Manager | Jacob Robbins |
| TER | 1.62 (28-Feb-2012) |
| Minimum Investment | |
|---|---|
| Initial | $100000 |
| Additional | $500 |
| Savings | $100 |
| Charges | |
|---|---|
| Initial | 4.50% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | -0.01 |
You are here: research